论文部分内容阅读
抗生素被作为制癌药物的研究对象,早自本世纪初叶已开始(Reilly,1953)。40多年前 Uhlenhuth 和 Beck 报告的绿脓酶(Pyocyanase),可认为系最早被分离的有制癌效能的抗生素。但因其毒性甚大,使这一研究未能继续进行。以后由于青霉素的发现,及其在制菌方面研究的进展,使得抗肿瘤药物的研究也被引至这方面。Cornman,1944,1945;Beard,1944;Lewis,1944;Gey,Gey,Inui和 Vedder,1945;Stock,Sugiura 和 Rhoads,1949等人进行了各种青霉素的抗
Antibiotics have been used as research targets for cancer-causing drugs and have begun as early as the beginning of this century (Reilly, 1953). Pyocyanase, reported by Uhlenhuth and Beck over 40 years ago, is considered to be the earliest isolated antibiotic with anticancer activity. However, because of its great toxicity, this study could not continue. Later, due to the discovery of penicillin and its progress in bacteriostatic research, research on anti-tumor drugs was also introduced to this area. Cornman, 1944, 1945; Beard, 1944; Lewis, 1944; Gey, Gey, Inui and Vedder, 1945; Stock, Sugiura and Rhoads, 1949, et al.